Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$122.97 USD

122.97
701,655

-0.38 (-0.31%)

Updated Dec 2, 2022 04:04 PM ET

After-Market: $122.99 +0.02 (0.02%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.51%
2Buy17.96%
3Hold9.47%
4Sell5.16%
5Strong Sell2.21%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 250)

Industry: Medical - Products

Trades from $1

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.

Zimmer Biomet (ZBH) Surpasses Q3 Earnings and Revenue Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of 1.28% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Earnings Expected to Grow: Should You Buy?

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.

Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System

Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.

Zimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains?

Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zimmer Biomet (ZBH) Procedure Recovery Strong, Margin Woe Stays

Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.

Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight

Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.

Zimmer (ZBH) Down 8% Since Last Earnings Report: Can It Rebound?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Indrajit Bandyopadhyay headshot

4 Stocks to Watch Amid Recovering Medical Products Industry

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down

Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.

Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.

Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered

Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.

Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth

Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.

Lantheus Holdings, Inc. (LNTH) Hits Fresh High: Is There Still Room to Run?

Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss

OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.

Inogen (INGN) Q2 Earnings and Revenues Beat Estimates

Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.

Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates

Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.

ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?

ZBH vs. LMAT: Which Stock Is the Better Value Option?

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up

The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.

Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.